SAB Biotherapeutics (SABS) Earnings Date & Reports

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

SABS is expected to report earnings to rise 74.29% to -61 cents per share on August 06

SAB Biotherapeutics SABS Stock Earnings Reports

Q2'26

Est.

$-0.61

Q1'26

Beat

by $0.23

Q4'25

Missed

by $0.13

Q3'25

Missed

by $0.09

Q2'25

Missed

by $0.98

The last earnings report on May 12 showed earnings per share of -34 cents, beating the estimate of -57 cents. With 352.05K shares outstanding, the current market capitalization sits at 259.21M.

View a ticker or compare two or three

Compare

SABS

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for SABS